What We Do
Boost sensitivity in genomics by removing undesired fragments prior to sequencing with DepleteX™
Whole Genome Sequencing
Repetitive DNA
Single Cell Sequencing
Ribosomal, mitochondrial, and non-variable genes
Bulk RNA-Seq
Abundant ribosomal, mitochondrial, globin, and housekeeping genes
The massive throughput increase of sequencing technology has powered a new era of genomics. Unfortunately, sequencing reads are wasted on abundant and uninformative sequences that limit the ability to detect lower abundance signals. This is the classic ‘needle in a haystack’ problem of genomics. Our solution? DepleteX technology removes fragments prior to sequencing and removes the haystack to better see all the needles in a sample.
DepleteX technology harnesses the specificity of CRISPR-Cas9 to degrade abundant, uninformative sequences in next-generation sequencing (NGS) libraries. Sequencing reads are then spent on fragments of interest so you can better see low level gene expression, boost somatic mutation detection, or better detect pathogens in metagenomic samples.
Now you can see exactly what you want, breaking through the clutter—and breaking new ground.
Benefits of DepleteX technology
Highly programmable
Increases sensitivity
Simple automatable workflow
Genomic analysis
platform agnostic
How DepleteX works
DepleteX mediated depletion can be integrated directly into NGS library prep protocols at various points depending on the application. CRISPR-Cas9 complexes are formed with a pool of designed guide RNAs. After targeted sequences are cut, they cannot be PCR amplified and are excluded from a sequencing library.
Applications
DepleteX technology is a scalable and specific removal method for unwanted sequences for many applications.
View the applications below to learn how Jumpcode is driving discovery today.
Single Cell Analysis
Gain a deeper view of expression profiles of individual cells
Microbiome
Characterize microbial populations and their impact on human health
Infectious Disease Surveillance
Detect known and novel pathogens to accelerate outbreak investigations
Whole Transcriptome Profiling
Measure gene and transcript activity to interrogate gene expression patterns
Customer Story – ImYoo
Isolating informative RNA gives ImYoo™ greater power to grow their business.
ImYoo is a single-cell transcriptomics startup that helps biopharma companies stratify study participants to optimize clinical trials. The company is using single-cell gene expression profiling to understand immune variability and personalize information.
For the US patent, the patent number is US 10,604,802 entitled Genome Fractioning. The patent publication is available here.
For the EP patent, the patent number is EP3102722 entitled Genome Fractioning. The patent publication is available here.